Pierre Fabry forges I/O discovery pact; Actinium surges on CHMP support
→ France’s Pierre Fabre struck a deal with H-Immune SAS to develop new immunotherapies, utilizing H-Immune’s technology platform to generate lead candidates of fully human …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.